Hinge Health, Inc.
In the published model solve dated 2026-Q2, anchored at $95.57, Hinge Health, Inc. (HNGE) is priced for today's economics sustained for ~13.6 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Hinge Health sells digital musculoskeletal care to employers and health plans on an annual subscription where, per its 10-K, ⟦clients only pay for members that engage with our programs⟧, so engagement is both the product and the revenue lever. • The defining recent fact is the profitability inflection: Q1 2026 revenue grew 47% to $182 million with an 85% gross margin and a 25% operating margin, and free cash flow turned to $42 million, a tenfold jump year over year. [Source: Q1 2026 earnings c
Is HNGE overvalued? See what's priced in →
194 institutional managers reported holding HNGE in 13F filings for the quarter ended 2026-03-31. Together they hold about 67% of the company; the top 10 hold 35%. 56 opened new positions that quarter. Held by Vanguard Group, Arrowstreet Capital, Citadel Advisors, among others. On the short side, 5.8M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (2.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
No open-market insider buys on file at HNGE over the trailing three years. Absence is a fact about the company, not a signal. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
HNGE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2025-11-08 | -9.4% | +7.6% |
| 2026-03-04 | +20.5% | +20.0% |
| 2026-05-08 | +12.0% | pending |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
HNGE's latest 8-K filings: 2026-08-21 (items 1.01, 2.03); 2026-08-04 (items 2.02, 7.01, 8.01, 9.01); 2026-06-09 (items 7.01, 9.01); 2026-06-04 (items 5.07); 2026-05-05 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.